🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

163 results for “Ark” Clear

  1. 11C-SB207145, 11C-DASB

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Parkinson's disease, Prodromal phase of Parkinson's disease

    phase 3 small molecule active

    1 trial

  2. ARD-101

    Ark Therapeutics

    Hyperphagia

    phase 3 small molecule on hold

    1 trial

  3. Apremilast, Apremilast, Apremilast

    Amgen Technology (Ireland) UC

    Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).

    phase 3 small molecule active

    1 trial

  4. Atomoxetine Aurobindo 40 mg hard capsules, Microcrystalline cellulose gelatin capsule

    Disc Medicine

    Parkinson's disease

    phase 3 small molecule active

    1 trial

  5. BHV-8000, DaTSCAN 74 MBq/ml solution for injection, DaTSCAN 74 MBq/ml solution for injection, BHV-8000, Placebo for BHV-8000

    Biohaven Bioscience Ireland Limited

    Early Parkinson’s Disease

    phase 3 small molecule active

    1 trial

  6. BIIB122

    Denali Therapeutics

    Parkinson Disease

    phase 3 small molecule active

    2 trials

  7. CEP-1347 10mg

    Teva Pharma GmbH

    Parkinson Disease

    phase 3 small molecule terminated

    1 trial

  8. Commercially available 0,9 % sterile saline solution with marketing authorization will be utilized as the placebo., KEYTRUDA 25 mg/mL concentrate for solution for infusion, INBRX-106, INBRX-106

    Inhibrx Biosciences

    Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  9. Dipraglurant

    Addex Therapeutics

    Parkinson Disease

    phase 3 small molecule terminated

    2 trials

  10. H006629, H006629, H006629, LEVODOPA AND DECARBOXYLASE INHIBITOR , H006629

    Zambon SpA

    Motor fluctuations in advanced Parkinson’s disease

    phase 3 small molecule active

    1 trial

  11. PEMETREXED, PEMBROLIZUMAB, CISPLATIN, PACLITAXEL, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN

    Cancer Prevention Pharma (Ireland) Limited

    Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment with a PD-1 antagonist (pembrolizumab) according to the European Marketing Authorisation in a first line

    phase 3 small molecule active

    1 trial

  12. Pimavanserin tartrate (ACP-103)

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease Psychosis

    phase 3 small molecule completed

    4 trials

  13. Placebo

    Black Diamond Therapeutics

    Parkinsons Disease (PD)

    phase 3 small molecule active

    1 trial

  14. Placebo

    Ark Therapeutics

    Hyperphagia

    phase 3 small molecule on hold

    1 trial

  15. RO7046015, Placebo Prasinezumab

    Roche Registration Limited

    Early-Stage Parkinson’s Disease (PD)

    phase 3 small molecule active

    1 trial

  16. RO7046015, RO7046015, RO7046015 Placebo

    Roche Registration Limited

    Early Parkinson's disease

    phase 3 small molecule active

    1 trial

  17. Revlimid 10 mg hard capsules, Zelvina 10 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion, Zelvina 15 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 5 mg hard capsules, Revlimid 20 mg hard capsules, 0.9% saline solution for infusion. The placebo (250 mL infusion container with 0.9% (w/v) sodium chloride for injection) is being sourced locally from commercial market and delivered to an unblinded pharmacy., Revlimid 15 mg hard capsules, Truxima 100 mg concentrate for s

    Incyte Biosciences Distribution B.V.

    follicular lymphoma (FL) and marginal zone lymphoma (MZL)

    phase 3 small molecule active

    1 trial

  18. Rivastigmine Transdermal System

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 3 small molecule completed

    1 trial

  19. Safinamide 100 mg PLACEBO: Safinamide 100 mg PLACEBO film-coated tablets have the same composition as the relevant Investigational Medicinal Products except for the presence of Active Substance that is missing in the placebo formulations. The missing amount of active substance Safinamide methanesulfonate is replaced in the PLACEBO formulation with the same amount of Microcrystalline cellulose, one of the excipients already present in the authorised formulation, Xadago 100 mg film-coated tablets, Xadago 50 m

    Verona Pharma Ireland Limited

    PARKINSON’S DISEASE WITH MOTOR FLUCTUATIONS

    phase 3 small molecule active

    1 trial

  20. Saline, 0.9% sodium chloride solution IV infusion marketed authorized will be used as the placebo and will be supplied by the site. the SmPC previously authorized are Country specific. for Belgium, Spain and Sweden per local requirements under CTDs no SmPCs were submitted., Delandistrogene moxeparvovec-rokl

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  21. TVP-1012

    Takeda Pharmaceuticals International AG

    Parkinson's Disease

    phase 3 small molecule completed

    1 trial

  22. TVP-1012 1mg

    Takeda Pharmaceuticals International AG

    Parkinson's Disease

    phase 3 small molecule completed

    3 trials

  23. apomorphine infusion

    SUPERNUS PHARMACEUTICALS, INC.

    Idiopathic Parkinson's Disease

    phase 3 small molecule active

    1 trial

  24. pimavanserin tartrate

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease Psychosis

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources